Trial · NCT05951192
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
NCT05951192, Phase 4, Completed, USRC Kidney Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease. Trials, record NCT05951192. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05951192
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
- NCT number
- NCT05951192
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 161 participants, actual
- Lead sponsor
- USRC Kidney Research
- Conditions
- Anemia, Renal Insufficiency, Chronic, Renal Anemia
- Interventions
- Daprodustat
- First posted
- 2023-07-18
- Last updated
- 2024-05-24
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in hemoglobin from baseline to the effectiveness evaluation period | 120 days | Change in hemoglobin from baseline (defined as the mean of all available hemoglobin values obtained in the 30 days prior to Day 1) to the effectiveness evaluation period (mean of all available hemoglobin values obtained in the 30 days prior to Day 120). |
| Secondary | The number/proportion of subjects with a hemoglobin in target range of 10-11 g/dL from baseline to effectiveness evaluation period | 120 days | The number/proportion of subjects with a hemoglobin in target range of 10-11 g/dL from baseline to effectiveness evaluation period |
| Secondary | The number/proportion of subjects with a change in hemoglobin under 0.5 g/dL from baseline to effectiveness evaluation period | 120 days | The number/proportion of subjects with a change in hemoglobin under 0.5 g/dL from baseline to effectiveness evaluation period |
| Secondary | Number of hemoglobin excursions that are < 8.5 g/dL or ≥ 12 g/dL during the treatment period. | 120 days | Number of hemoglobin excursions that are \< 8.5 g/dL or ≥ 12 g/dL during the treatment period. |
| Secondary | Number of dose adjustments in daprodustat per patient during the treatment period | 120 days | Number of dose adjustments in daprodustat per patient during the treatment period |
| Secondary | Number of subjects retained on daprodustat therapy from Day 1 through Day 120 | 120 days | Number of subjects retained on daprodustat therapy from Day 1 through Day 120 |
| Secondary | The number/proportion of subjects who receive a refill prescription with the correct prescribed dose with no gap (0 days) in drug supply from the previous prescription | 120 days | The number/proportion of subjects who receive a refill prescription with the correct prescribed dose with no gap (0 days) in drug supply from the previous prescription |
| Secondary | The time (in days) from initial and refill prescription to delivery to patient | 120 days | The time (in days) from initial and refill prescription to delivery to patient |
| Secondary | Average monthly (percent) compliance with daprodustat daily dosing, per subject report. | 120 days | The average monthly compliance will be calculated from individual subject reported verbal estimates of (percent) compliance with daprodustat daily administration. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05951192
GET https://conductscience.org/api/trials/v1/NCT05951192/registered